Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Sphingolipids in Adipose: Kin or Foe?

Valentine Y., Cowart LA.

Animal Study, published in Adv Exp Med Biol (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Exp Med Biol (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35503171
PMCID
PMC11154088
DOI
10.1007/978-981-19-0394-6_2
Citations
3

Abstract (original English)

Obesity research has shifted in recent years to address not only the total amount of adipose tissue present in an individual but also to include adipose tissue functions such as endocrine function and thermogenesis. Data suggest that sphingolipids are critical regulators of metabolic homeostasis, and that disruption of their levels is associated with metabolic disease. Abundant data from mouse models has revealed both beneficial and deleterious roles for sphingolipids in adipose function, and numerous human studies have shown that obesity alters circulating sphingolipid profiles. Sphingolipids comprise a large family of interrelated metabolites, and pinpointing specific functions for specific lipids will be required to fully exploit the therapeutic potential of targeting sphingolipids to treat obesity and related disorders.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsMiceMetabolic DiseasesObesitySphingolipidsThermogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.